Breo Ellipta carries a retail price of roughly $400 to $500 for a single 30-dose inhaler, making it one of the more expensive maintenance inhalers on the market. Several factors drive that price: patent protection that runs through 2030, a proprietary inhaler device, limited generic competition, and the pricing leverage that comes with being a combination drug in a therapeutic class where switching isn’t simple. The good news is that recent manufacturer commitments have capped the out-of-pocket cost at $35 per month for many patients.
What Breo Ellipta Actually Does
Breo combines two active ingredients into a single inhaler. One is a corticosteroid that reduces inflammation in the airways. The other is a long-acting bronchodilator that relaxes the smooth muscle lining your airways, keeping them open. Together, they treat both the underlying inflammation and the tightness that cause symptoms in asthma and COPD.
The key selling point over older combination inhalers is convenience: Breo is dosed once daily, one puff per day, compared to twice-daily dosing for competitors like Advair. That 24-hour duration of action was a meaningful clinical advantage when Breo launched, and it’s part of what allowed GSK to price it at a premium.
Patent Protection Through 2030
The single biggest reason Breo remains expensive is patent exclusivity. According to FDA records, the last qualifying U.S. patent on the drug combination doesn’t expire until October 2030. That gives GSK roughly five more years of market protection, during which no competitor can sell a true generic version without a legal challenge.
While the FDA has technically approved authorized generic versions of Breo through Prasco Laboratories, these products do not appear to be commercially available yet. An “authorized generic” is made by or for the brand-name company itself, so even when it does launch, the pricing may not drop as dramatically as patients hope. The real price competition typically arrives when multiple independent manufacturers enter the market, and that’s unlikely to happen at scale before the patents expire.
The Ellipta Device Adds Complexity
Breo isn’t just a medication. It’s a medication packaged inside a proprietary dry powder inhaler called the Ellipta. The device uses a two-strip design where each active ingredient is stored in its own sealed blister strip, kept separate until the moment you inhale. When you open the cover and breathe in, one dose from each strip is aerosolized simultaneously.
This design has practical benefits: the three-step operation (open, inhale, close) is simpler than many older inhalers, and keeping the two drugs physically separated until use allows each formulation to be optimized independently. But it also means any generic competitor has to replicate not just the drug formulation but the delivery device, which requires its own engineering, manufacturing lines, and regulatory approval. Device patents layer on top of drug patents, creating additional barriers to competition.
Insurance Coverage Is Inconsistent
How much you actually pay for Breo depends heavily on your insurance plan. Many commercial insurers place Breo on a preferred brand tier with a copay of $30 to $75, but others classify it as non-preferred or require prior authorization before covering it. The VA system, for example, lists fluticasone/vilanterol as non-formulary, meaning veterans need special approval to get it dispensed.
If your plan doesn’t cover Breo or places it on a high-cost specialty tier, you can end up facing the full retail price or a steep coinsurance percentage. This is where the sticker shock hits hardest, particularly for patients on high-deductible plans who pay retail prices until their deductible is met.
The $35 Cap for Many Patients
In 2024, GSK announced a $35 monthly out-of-pocket cap on several of its inhaler products, including Breo Ellipta. This came alongside similar commitments from AstraZeneca and Boehringer Ingelheim, partly in response to pressure from the Biden administration and broader conversations about inhaler affordability.
For patients with commercial insurance or Medicare, this cap can dramatically reduce what you pay at the pharmacy. It doesn’t lower the list price of the drug itself, so GSK still collects the difference from insurers. But if your primary concern is what leaves your wallet each month, the cap makes Breo significantly more accessible than its retail price suggests. Check whether your specific plan qualifies, since the details vary by insurer and coverage type.
Why Inhaler Prices Stay High Generally
Breo’s pricing isn’t unusual in the inhaler market. Nearly all brand-name combination inhalers cost $300 to $600 at retail. The pattern repeats across the category for a few structural reasons. Inhalers are drug-device combinations, which means the regulatory pathway for generics is more complex than for a simple pill. Each device design carries its own patents. And because switching inhalers can affect how well medication reaches your lungs, doctors and patients are often reluctant to change what’s working, which reduces competitive pressure even when alternatives exist.
The combination of patent layering, device complexity, and clinical switching costs gives manufacturers sustained pricing power. Until Breo’s patents expire and multiple independent generics enter the market, the list price is unlikely to fall significantly. In the meantime, the $35 cap, manufacturer savings cards, and checking whether your insurer prefers a therapeutic alternative are the most practical ways to reduce what you pay.